Healio
SearchLoading
Healio
SearchLoading
Image of scalp psoriasis

Take Homes in Psoriasis
ByDavid Statman
Fact checked byKristen Dowd

Read more

February 21, 2024
1 min watch
Save

VIDEO: Risankizumab ‘easy drug to discuss’ with psoriasis patients

ByDavid Statman
Fact checked byKristen Dowd

In this Healio exclusive video, Raj Chovatiya, MD, PhD, discussed research into the interleukin-23 inhibitor risankizumab from the Maui Derm 2024 meeting.

Chovatiya, assistant professor of dermatology at Northwestern University Feinberg School of Medicine, discussed long-term studies into the use of risankizumab (Skyrizi, AbbVie) to treat palmoplantar psoriasis, as well as a long-term safety analysis.

“That safety looks very, very encouraging and makes it a really easy drug to discuss with our patients,” Chovatiya said.

Sources/Disclosures

Collapse
Source: Healio Interview
Disclosures: Chovatiya reports being an advisor, consultant, speaker and/or investigator for AbbVie, Apogee Therapeutics, Arcutis, Argenx, ASLAN Pharmaceuticals, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Dermavant, Eli Lilly and Company, FIDE, Galderma, Genentech, GSK, Incyte, Janssen, LEO Pharma, L’Oréal, Nektar Therapeutics, Opsidio, Pfizer Inc., Regeneron, RAPT, Sanofi and UCB.

Read more from Take Homes in Psoriasis

View all

Read more about

palmoplantar psoriasis
risankizumab
psoriasis
 

Related Content